• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Cannabis » Chemistree OTCQB: CHMJF (CSE: CHM) Acquires Ownership Stake in The Physician’s Choice CBD LLC

Chemistree OTCQB: CHMJF (CSE: CHM) Acquires Ownership Stake in The Physician’s Choice CBD LLC

Drew Hendricks by Drew Hendricks
May 30, 2019
in Cannabis
3 min read
499
0

Chemistree Technology Inc. (CSE: CHM and CHM.wt) (USOTCQB: CHMJF) announced a funding agreement with The Physician’s Choice LLC, a leader in research, development, and utilization of quality hemp-derived cannabidiol or CBD.

In a statement released by Chemistree’s President, Karl Kottmeier, the investment poses as a “great opportunity” for the company to leverage and integrate cannabis assets on a much larger scale.

“The investment we are making into PCCBD gives us exposure to an entirely new industry,” says Kottmeier.

Cannabidiol or CBD has become a popular household name with over 50 states legalizing and recognizing the product as medicine for pain, diabetes, addiction, and epilepsy.

The surge of popularity and demand opens interest for the Food and Drug Administration to categorize CBD as hemp, a cannabis derivative with a deficient concentration of psychoactive compound delta-9-tetrahydrocannabinol or THC. The passing of Agriculture Improvement Act of 2018 or the 2018 Farm Bill removes hemp from the list of Controlled Substance, making CBD a fair trade product.

CBD for medical practice

Cannabidiol is a minor constituent of marijuana. However, the extract does not cause intoxication compared to marijuana’s primary concomitant, THC or delta-9-tetrahydrocannabinol. Unlike THC, CBD does not bind or act on CB1R or the cannabinoid receptor responsible for the high effect in marijuana.

Scientists, however, find traces of CBD binding with the other receptor called serotonin 5-HTIA which is responsible for regulating sleep, mood, anxiety, and pain.

CBD Oil
The wonders of CBD. Photo: Marco Verch/Flickr/CC BY 2.0

Back in 2013, Charlotte Figi’s story broke out in the national and international media scene. Charlotte, diagnosed with intractable pediatric epilepsy, experienced constant severe seizure since she was three months old. The child felt a glimpse of hope after she took oils extracted from marijuana that contains a higher dosage of CBD-to-THC.

The clinical evidence received from Charlotte’s case opened for the development of a drug named as Epidiolex, a CBD extract that the FDA recognizes as an effective treatment for Dravet syndrome and Lennox Gastaut syndrome.

CBD as an effective course for Pain Management

The National Academy of Medicine revealed that over 100 million Americans are living with chronic pain that significantly reduces an individual’s quality of life and ultimately, increase healthcare costs.

Treating chronic pain has been a “crossroad” according to The Physician’s Choice CBD. Jumping from various forms of pain medication and treatment posses harmful side-effects, end-organ damage, and possible addiction that concerned most medical practitioners.

Currently, doctors offer a myriad of different treatments like physical, interventional, and complementary therapies. Unfortunately, as discussed by PCCBD, are not enough to successfully treat and manage patients with complex pain.

“Managing various pain syndromes with medications that do not exacerbate severe medical conditions and behavioral risk factors is an ongoing challenge for medical professionals,” says PCCBD’s Dr. J. Julian Grove.

In light of these dilemmas, it becomes a driving force to develop a product line of cannabidiol that correctly manage specific pain syndromes.

Pain Therapeutic

Currently, all evidence for CBD’s effects on pain management comes from animal-based research. CBD injections and oral intake successfully prevented and reversed signs of neuropathic pain development. The drug successfully dissipates a sensation of pain caused by nonirritant stimuli.

Topical CBD significantly reduced the development of joint pain on mice with osteoarthritis. CBD gels also minimized swelling and inflammation on mice with arthritis.

Further, Topical CBD applied as a cream, oil, or sprays on children with epidermolysis bullosa made wounds heal faster, lessen blisters, and reduced pain. The most significant findings on Topical CBD is that parents who’ve used the drug for epidermolysis halted the use of oral opioid analgesic pain medication.

Drew Hendricks

Drew Hendricks

Drew Hendricks is a business technology and social marketing specialist. Drew has also written for many major publishers such as Forbes, Entrepreneur Magazine and The Huffington Post. Drew has also worked with a variety of different startups around the globe as well as larger advertising agencies in the United States and the UK.

Related Posts

Zenabis returned $1.9 million worth of pot  to Sundial over bad quality and visible molds
Cannabis

Zenabis returned $1.9 million worth of pot to Sundial over bad quality and visible molds

August 22, 2019
267
Tilray to start exporting medicinal pot to Germany
Cannabis

Tilray to start exporting medicinal pot to Germany

August 21, 2019
134
CannTrust stocks fell another 5% after weed distributor returned millions worth of pot
Cannabis

CannTrust stocks fell another 5% after weed distributor returned millions worth of pot

August 20, 2019
147
Cannabis stocks fell as possible recession brews
Cannabis

Cannabis stocks fell as possible recession brews

August 14, 2019
156
Hexo’s Stocks Continue To Suffer A Cannabis Stocks Dive
Cannabis

Aurora Cannabis hovers trade flat amid strong market

August 13, 2019
159
Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%
Cannabis

Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%

August 12, 2019
128
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.